logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 13 of 13 Items
Showing 1 - 13 of 13 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Journal Article
|
Research

Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India

Mongia H, Mamnoon F, Silsarma A, Mahajan R, Dalal A,  et al.
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-04-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
World Health Organization suggests concurrent bedaquiline-delamanid (BDQ-DLM) as part of individualised regimens for eligible patients with pulmonary drug-resistant tuberc...
Journal Article
|
Research

Operationalising targeted next-generation sequencing for routine diagnosis of drug-resistant TB

Iyer AS, Ndlovu Z, Sharma J, Mansoor H, Bharati M,  et al.
2023-06-21 • Public Health Action
2023-06-21 • Public Health Action
BACKGROUND
Phenotypic drug susceptibility testing (pDST) for Mycobacterium tuberculosis can take up to 8 weeks, while conventional molecular tests identify a limited set of resistanc...
Conference Material
|
Slide Presentation

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

High prevalence of bedaquiline and linezolid resistance in extensively drug-resistant tuberculosis patients in a Médecins Sans Frontières clinic, Mumbai, India

Khan S, Silsarma A, Iyer AS, Galindo MA, Chavan VV,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
Bedaquiline (BDQ) and linezolid (LZD) are Group A drugs and form part of shorter and longer BDQ-based regimens under India’s National Tuberculosis (TB) Programme. A syst...
Journal Article
|
Commentary

Caring for adolescents and young adults with tuberculosis or at risk of tuberculosis: Consensus statement from an international expert panel

Chiang SS, Waterous PM, Atieno VF, Bernays S, Bondarenko Y,  et al.
2023-03-01 • Journal of Adolescent Health
2023-03-01 • Journal of Adolescent Health
Journal Article
|
Research

Clinical utility of target-based next-generation sequencing for drug-resistant TB

Mansoor H, Hirani N, Chavan VV, Das M, Sharma J,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
In high TB burden countries, access to drug susceptibility testing is a major bottleneck. Targeted next-generation sequencing (tNGS) is a promising technology for rapid re...
Conference Material
|
Poster

Treatment outcomes among drug-resistant children below 10 years treated with newer drugs, in Médecins Sans Frontieres clinic in Mumbai, India

Singh SN, Singh P, Silsarma A, Iyer AS, Galindo MA,  et al.
2022-11-30 • MSF Paediatric Days 2022
2022-11-30 • MSF Paediatric Days 2022
Journal Article
|
Research

Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India

Laxmeshwar C, Das M, Mathur T, Israni T, Jha S,  et al.
2022-02-11 • PLOS One
2022-02-11 • PLOS One
BACKGROUND
People with drug-resistant tuberculosis (DR-TB) are known to suffer from many mental-health disorders. This study aims to describe the proportion of patients diagnosed wit...
Conference Material
|
Poster

Treatment outcomes of bedaquiline-exposed tuberculosis patients treated with a regimen containing bedaquiline and delamanid: findings from MSF clinic, Mumbai, India

Mongia H, Mansoor H, Mamnoon F, Silsarma A, Davuluri P,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Slide Presentation

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|
Video

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-06-07 • MSF Scientific Days International 2022
2022-06-07 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|
Abstract

Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India

Mansoor H, Hirani N, Chavan VV, Joshi A, Oswal V,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
In countries with a high tuberculosis (TB) burden, poor access to drug susceptibility testing is a major bottleneck in diagnosing drug-resistant (DR) TB. India is estima...